Siegfried's EVOLVE+ Gains Traction: Acquisitions, Complex Molecules, and a Sharper U.S. Focus
Half-year results confirm guidance as the CDMO integrates new sites and races to unlock capacity for next-generation small molecules.
SFZN.SW · Earnings Call · 2026-08-21
A Solid Half-Year, Confirmatory Numbers
Siegfried Holding AG reported half-year 2026 results that were squarely in line with the guidance issued at the closing of its recent acquisition. Net sales rose 4.8% in local currencies to CHF 633 million, while core EBITDA margin expanded to 22.4% from 21.6%. This performance was driven by productivity gains, a favorable product mix, and disciplined cost control, as new CFO Tania Micki emphasized: “What has particularly impressed me is the relentless focus on operational excellence throughout the organization, which remains a core pillar of our EVOLVE+ strategy.” — Tania Micki, CFO · 2026-08-21 The company confirmed its full-year guidance of high single-digit growth and an EBITDA margin above 23%. The confidence stems from the integration progress of the three acquired Drug Substances sites in the U.S. and Australia, which closed on May 1, and the strong commercial momentum in the Drug Substances business. The acquisition contributed for only two months, but management re-affirmed the USD 100 million annualized contribution target. In the first half, the cubic meter of freed capacity is already being marketed aggressively, with three concrete offers submitted to top-tier pharmaceutical companies.EVOLVE+ Strategy: From Blueprint to Momentum
Two years after the launch of the EVOLVE+ strategy, the evidence is mounting that the plan is working. The company has shifted its go-to-market approach, increased the sales force, and seen a 31% jump in RFPs in Drug Products and 69% more in Drug Substances. But the most striking signal is the shift in molecule complexity. CEO Marcel Imwinkelried noted: “I was sharing with you 1 year ago compared to the past when for an API, it was common to have 5 to 7, 8 synthesis steps. It went up to 20 synthesis steps last year. And we're really now also happy to share with you the newest generation of small molecules, our customers are asking us for 40 synthesis steps.” — Marcel Imwinkelried, CEO · 2026-08-21 This is not just a technical nuance—it reflects a structural tailwind. AI-driven drug design is pushing toward “golden molecules” with far greater complexity, and Siegfried is positioning itself as the go-to partner for these new molecule types. The company has already won three protein degrader projects, a category that is still nascent but growing fast. As Marcel put it, "We won also in Drug Substance as well. And this is well on track." The first revenues from these projects are expected to ramp from 2027 onward.U.S. Capacity: The Linchpin
The acquisition of the U.S. and Australian sites is central to the strategy. Siegfried now operates the largest global small-molecule Drug Substance CDMO network, with 10 sites across the U.S., Europe, and Asia. The expanded U.S. footprint is a major selling point, especially given the geopolitical uncertainty that makes customers seek supply reliability. The company is moving fast to integrate: the first transfer within Wilmington will be completed this year, and consolidation with Pennsville is underway. The goal remains to free up 80 cubic meters of high-quality capacity for innovative products from 2028 onward.The customer response has been tangible. Wilmington opened for visits in July; five visits have already occurred, with six more scheduled. More importantly, the company has submitted three offers for capacity. This is a clear sign that the cash generation potential from these assets is being unlocked, though the near-term cash flow is pressured by integration and inventory building.Our target remains unchanged to free up 80 cubic meters of high-quality capacity for innovative products available from 2028 onwards. We are on track.